Renalytix Plc
LSE:RENX

Jigglypop Analysis For Renalytix Plc 🤓

Renalytix trades at 6.25p, hovering just above its 52-week low of 5.5p and miles below the 15.5p high—squarely in the bottom third of its range. With the shares under the 200-day moving average (7.32p) and near the 50-day (6.46p), momentum is subdued despite a 1.6% daily uptick and flat month. This micro-cap remains a speculative story, not a value play: execution on U.S. clinical integrations and EHR single-click ordering must translate into paid volume. Recent updates show integrations live with initial testing and partnerships (Tempus AI, MVP Health Care), but management still flags uncertain timing for commercial outcomes. Expect volatility; catalysts hinge on contract wins and sustained test uptake across target health systems. Valuation screens cheap but risk remains elevated.

About Renalytix Plc 👋

Renalytix Plc develops AI-powered in vitro diagnostic solutions to aid the clinical management of kidney diseases in Europe and the United States. Its KidneyIntelX platform uses an AI-driven algorithm that integrates multiple data sources, including validated blood biomarkers, inherited genetic information, and personalized data from electronic health records, to generate an individualized patient risk score. The company’s products support kidney disease diagnosis and prognosis, clinical care, patient stratification for drug trials, and identification of drug targets. It maintains a license agreement with Mount Sinai Health System to develop and commercialize its products related to AI-driven kidney disease diagnostics. The firm was previously known as Renalytix AI plc and adopted the name Renalytix Plc in June 2021. Established in 2018, it is headquartered in London, United Kingdom.